National Institutes of Health (NIH) Recommend to Expand Its Scope of Research in the Development of National Institutes of Health (NIH)'s PLX-RAD Cells for the Treatment of Acute Radiation Syndrome

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HAIFA, Israel, July 18, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, has recommended to Pluristem that NIAID expand the scope of its ongoing animal research using PLX-RAD cells for the treatment of acute radiation syndrome (ARS).

Help employers find you! Check out all the jobs and post your resume.